We need your help! If you've ever found our data helpful, please take our impact survey (15 min). Your replies will help keep the data flowing to the scientific community. Please Click here for Survey

Unknown

Dataset Information

0

Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models.


ABSTRACT: Anaplastic lymphoma kinase (ALK) inhibitor crizotinib has proven to be effective in the treatment of ALK-mutated neuroblastoma, but crizotinib resistance was commonly observed in patients. We aimed to overcome crizotinib resistance by combining with the MEK inhibitor trametinib or low-dose metronomic (LDM) topotecan in preclinical neuroblastoma models.We selected a panel of neuroblastoma cell lines carrying various ALK genetic aberrations to assess the therapeutic efficacy on cell proliferation in vitro. Downstream signals of ALK activation, including phosphorylation of ERK1/2, Akt as well as HIF-1α expression were evaluated under normoxic and hypoxic conditions. Tumor growth inhibition was further assessed in NOD/SCID xenograft mouse models.All NBL cell lines responded to crizotinib treatment but at variable ED50 levels, ranging from 0.25 to 5.58 μM. ALK-mutated cell lines SH-SY5Y, KELLY, LAN-5, and CHLA-20 are more sensitive than ALK wild-type cell lines. In addition, we demonstrated that under hypoxic conditions, all NBL cell lines showed marked decrease of ED50s when compared to normoxia except for KELLY cells. Taking into consideration the hypoxia sensitivity to crizotinib, combined treatment with crizotinib and LDM topotecan demonstrated a synergistic effect in ALKF1174L-mutated SH-SY5Y cells. In vivo, single-agent crizotinib showed limited antitumor activity in ALKF1174L-mutated SH-SY5Y and KELLY xenograft models; however, when combined with topotecan, significantly delayed tumor development was achieved in both SH-SY5Y and KELLY tumor models.Oral metronomic topotecan reversed crizotinib drug resistance in the ALKF1174L-mutated neuroblastoma preclinical model.

SUBMITTER: Zhang L 

PROVIDER: S-EPMC5491461 | BioStudies | 2017-01-01

SECONDARY ACCESSION(S): 10.1016/j.tranon.2017.04.008

REPOSITORIES: biostudies

altmetric image

Publications

Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALK<sup>F1174L</sup> Drug-Resistant Neuroblastoma Preclinical Models.

Zhang Libo L   Wu Bing B   Baruchel Sylvain S  

Translational oncology 20170627 4


<h4>Background</h4>Anaplastic lymphoma kinase (ALK) inhibitor crizotinib has proven to be effective in the treatment of ALK-mutated neuroblastoma, but crizotinib resistance was commonly observed in patients. We aimed to overcome crizotinib resistance by combining with the MEK inhibitor trametinib or low-dose metronomic (LDM) topotecan in preclinical neuroblastoma models.<h4>Methods</h4>We selected a panel of neuroblastoma cell lines carrying various ALK genetic aberrations to assess the therapeu  ...[more]

Similar Datasets

2011-01-01 | S-EPMC3093683 | BioStudies
1000-01-01 | S-EPMC5689606 | BioStudies
2016-01-01 | S-EPMC4755925 | BioStudies
2012-01-01 | S-EPMC3316580 | BioStudies
2011-01-01 | S-EPMC3319004 | BioStudies
2014-01-01 | S-EPMC4226718 | BioStudies
2016-01-01 | S-EPMC4707106 | BioStudies
1000-01-01 | S-EPMC3219872 | BioStudies
2015-11-21 | E-GEOD-73292 | ArrayExpress
2019-01-01 | S-EPMC6396392 | BioStudies